Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors
Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Nigel S. Key(University of North Carolina at Chapel Hill), Diana S. Beardsley(Yale University), C. Thomas Kisker(Hemophilia Center of Western Pennsylvania), Bruce M. Ewenstein(CSL (United States)), Cathy G. Rosenfield(Tufts University), Horace E. Smith(Lurie Children's Hospital), Joan Gill(Great Lakes Institute of Management), Amy Shapiro(Riley Hospital for Children), Gerald Gilchrist(Mayo Clinic), Edwin G. Taft(Albany Medical Center Hospital), George Davignon(University of California San Diego), Jeanne M. Lusher(Science Factory), Herbert Cooper(University of North Carolina at Chapel Hill), W. Keith Hoots, Bertil Glader(Stanford University)
Cited by 355
Related Papers
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
|Journal of Clinical Oncology|2019|1.5k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
|Journal of Internal Medicine|1994|613